持续乙型肝炎病毒复制并接受长期替诺福韦或恩替卡韦治疗的丁型肝炎合并肝硬化患者的临床结局
前瞻性随访56例(48例肝硬化)慢性HDV感染且HBV复制、接受长期恩替卡韦或替诺福韦治疗的患者,中位随访50个月,全部实现HBV DNA抑制;与1:1匹配的HBV单感染患者相比,HDV患者死亡/肝移植、失代偿及HCC发生率均更高。
要点
- HDV合并晚期肝病患者长期强效核苷(酸)类似物治疗下HBV DNA均获抑制。
- HDV患者死亡/肝移植率为2.92/1000患者月,HBV单感染为0.38(P<0.001)。
- HDV患者HCC发生率约为HBV单感染的三倍(3.12 vs 1.12,P=0.02)。
核心结论
- 在接受强效核苷(酸)类似物长期抑制HBV DNA期间,HDV感染合并晚期肝病患者较HBV单感染患者仍维持较高的严重临床事件风险。
研究设计与样本
- 前瞻性随访研究,每3-6个月随访一次,56例HDV患者(48例肝硬化)接受长期恩替卡韦或替诺福韦治疗,中位随访50个月。
- HBV单感染接受相同治疗的患者按年龄、性别、血小板计数、白蛋白水平、胆红素和INR进行1:1匹配作为参照。
主要发现
- 56例HDV患者全部实现HBV DNA抑制。
- 死亡或肝移植发生于19例患者,HDV患者发生率为2.92/1000患者月 vs HBV单感染患者0.38/1000患者月(P<0.001)。
- 失代偿发生率HDV患者为1.53/1000患者月 vs HBV单感染患者0.13/1000患者月(P=0.015)。
- HCC发生率HDV队列为3.12/1000患者月 vs HBV单感染1.12/1000患者月(P=0.02),前者约为后者的三倍。
- 血小板计数、Child-Pugh评分及边缘性HDV感染与HCC发生相关。
关键数值与推荐
- HDV患者死亡/肝移植率2.92/1000患者月 vs HBV单感染0.38/1000患者月(P<0.001)。
- HDV患者失代偿率1.53/1000患者月 vs HBV单感染0.13/1000患者月(P=0.015)。
- HDV患者HCC发生率3.12/1000患者月 vs HBV单感染1.12/1000患者月(P=0.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Suppression of hepatitis B virus (HBV) replication with nucelos(t)ide analogues should be considered for patients with chronic hepatitis D virus (HDV) infection and ongoing HBV replication. AIM: To verify the clinical outcome after long-term entecavir or tenofovir treatment in patients with advanced fibrosis/cirrhosis, ineligible to peg-interferon therapy. METHODS: Patients were prospectively followed-up at 3-6 month intervals; measured outcomes were decompensation, hepatocellular carcinoma (HCC), liver transplant and liver related death. HBV monoinfected patients receiving the same treatment served as reference after 1:1 matching by age, gender, platelet count, albumin level, bilirubin and INR. RESULTS: 56 HDV patients (48 with cirrhosis; median follow-up 50 months) were enrolled; all achieved HBV DNA suppression. Death or liver transplant occurred in 19 patients, with a rate (n/1000 patient-months) of 2.92 in HDV patients vs 0.38 in HBV monoinfected patients (P < 0.001); similarly, decompensation occurred at a rate of 1.53 vs 0.13 (P = 0.015), respectively, and the rate of HCC was almost thrice in HDV cohort (3.12 vs 1.12; P = 0.02) Platelet count, Child-Pugh score and marginally HDV infection were associated with HCC development. CONCLUSION: Patients with HDV infection and advanced liver disease maintain an increased risk of severe clinical events as compared with HBV monoinfected patients, during prolonged HBV DNA suppression with potent NA.
引用
- Brancaccio G, Fasano M, Grossi A, et al. Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. Aliment Pharmacol Ther. 2019. PMID: 30793345. doi:10.1111/apt.15188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。